Selenium Thyroid Health Randomized Trial: What the Evidence Says

Quick Answer

Selenium Thyroid Health Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Subsequent studies expanded the evidence base but introduced uncertainty: a Mexican randomized study suggested improved clinical activity and reduced progression in mild GO, whereas trials in Sel-sufficient settings and in inactive moderate-to-severe GO have reported more heterogeneous effects. [Kostadinov Nikolay (2026); evidence level 1]
• It is associated with elevated anti-thyroid peroxidase antibodies (TPOAb) and often anti-thyroglobulin antibodies (TgAb). [Personius Lydia (2026); evidence level 4]
• The incidence of HT has increased over recent decades and is higher with advancing age, in women, and in iodine-sufficient populations. [Personius Lydia (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For selenium thyroid health randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Kostadinov Nikolay (2026). Efficacy of Selenium Supplementation in Graves’ Orbitopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis. DOI: 10.3390/jcm15124710. PMCID: PMC13302020. PMID: 42355878. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13302020/
• Personius Lydia (2026). Beyond levothyroxine: a narrative review of adjunctive management strategies for Hashimoto’s thyroiditis. DOI: 10.21037/gs-2025-1-554. PMCID: PMC13184362. PMID: 42164686. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13184362/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.